Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Cell Analysis of CXCL13+PD1+ CD8 T Cell in Association With Resistance to Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

NCT05894889 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05894889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05894889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Cell Analysis of CXCL13+PD1+ CD8 T Cell in Association With Resistance to Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2024
Completion date
August 1, 2027
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage iia non-small cell lung cancer, stage iib non-small cell lung cancer, stage iiia non-small cell lung cancer, stage iiib(n2) non-small cell lung cancer